Recommendation 5.4
➤ No recommendations can be made regarding the frequency and
duration of surveillance in patients at increased risk (See RISK) who are
asymptomatic and have no evidence of cardiac dysfunction during their
6–12 month post-treatment echocardiogram. (IC-B/H-Ins)
Recommendation 5.5
➤ Clinicians should regularly evaluate and manage cardiovascular risk
factors such as smoking, hypertension, diabetes, dyslipidemia, and
obesity in patients previously treated with cardiotoxic cancer therapies.
A heart-healthy lifestyle, including the role of diet and exercise, should
be discussed as part of long-term follow-up care.
(Moderate Recommendation; EB/IC-B-I)
